Richard J. Barry, a long-time stockholder of the Company, has served as a member of our Board since June 2015. He serves as member and Chair of the Nominating and Corporate Governance committee and as a member of the Audit committee and the Compensation committee.
Mr. Barry has served as a director for Elcelyx Therapeutics, a pharmaceutical company, since February 2013, and is a managing member of GSM Fund, LLC, a fund established for the sole purpose of investing in Elcelyx.
Mr. Barry has also been a Partner and Advisory Board member of the San Diego Padres since 2009. He was previously an Advisory Board member for the Schreyer Honors College at Pennsylvania State University, and served as a director of Cluster Wireless, a San Diego–based software company.
Mr. Barry has extensive experience in the investment management business. He was a founding member of Eastbourne Capital Management LLC, a large equity hedge fund investing in a variety of industries, including healthcare, and served as a Managing General Partner and Portfolio Manager from 1999 until its close in 2010. Prior to Eastbourne, Mr. Barry was a Portfolio Manager and Managing Director of Robertson Stephens Investment Management. He also spent over 13 years in various roles in institutional equity and investment management firms, including Lazard Freres, Legg Mason, and Merrill Lynch. In May 2019, Mr. Barry was appointed to the Board of Directors of MiMedx Group Inc., a biopharmaceutical company developing, manufacturing, and marketing regenerative biologics utilizing human placental allografts.
Mr. Barry holds a BA from Pennsylvania State University.
What is Richard Barry's net worth?
The estimated net worth of Richard Barry is at least $17.18 million as of November 3rd, 2023. Mr. Barry owns 140,000 shares of Sarepta Therapeutics stock worth more than $17,183,600 as of December 26th. This net worth evaluation does not reflect any other assets that Mr. Barry may own. Learn More about Richard Barry's net worth.
How do I contact Richard Barry?
Has Richard Barry been buying or selling shares of Sarepta Therapeutics?
Richard Barry has not been actively trading shares of Sarepta Therapeutics during the last ninety days. Most recently, on Friday, November 3rd, Richard Barry bought 50,000 shares of Sarepta Therapeutics stock. The stock was acquired at an average cost of $78.81 per share, with a total value of $3,940,500.00. Following the completion of the transaction, the director now directly owns 140,000 shares of the company's stock, valued at $11,033,400. Learn More on Richard Barry's trading history.
Who are Sarepta Therapeutics' active insiders?
Sarepta Therapeutics' insider roster includes Bilal Arif (EVP, Chief Technical Operations Officer), Richard Barry (Director), M. Behrens (Director), Kathryn Boor (Director), Joseph Bratica (Insider), Ryan Brown (EVP), Michael Chambers (Director), Ian Estepan (EVP, Chief Financial Officer), David Howton (EVP), Douglas Ingram (CEO), Stephen Mayo (Director), Dallan Murray (EVP, Chief Customer Officer), Louise Rodino-Klapac (Insider), and Hans Wigzell (Director). Learn More on Sarepta Therapeutics' active insiders.
Are insiders buying or selling shares of Sarepta Therapeutics?
In the last twelve months, Sarepta Therapeutics insiders bought shares 1 times. They purchased a total of 37,038 shares worth more than $4,955,684.40. In the last twelve months, insiders at the biotechnology company sold shares 11 times. They sold a total of 90,668 shares worth more than $13,164,125.22. The most recent insider tranaction occured on December, 12th when Director Hans Lennart Rudolf Wigzell sold 10,500 shares worth more than $1,310,820.00. Insiders at Sarepta Therapeutics own 7.7% of the company.
Learn More about insider trades at Sarepta Therapeutics. Information on this page was last updated on 12/12/2024.
